Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 7:27 pm Purchase |
2024-09-30 | 13G | NLS Pharmaceutics AG NLSP |
Lind Global Fund II LP | 103,530 8.100% |
103,530 (New Position) |
Filing History |
| 2024-11-14 7:25 pm Purchase |
2024-09-30 | 13G | Sintx Technologies, Inc. SINT |
Lind Global Fund II LP | 71,500 5.100% |
71,500 (New Position) |
Filing History |
| 2024-11-14 7:25 pm Purchase |
2024-09-30 | 13G | Netcapital Inc. NCPL |
Lind Global Fund II LP | 119,000 9.900% |
119,000 (New Position) |
Filing History |
| 2024-11-14 7:24 pm Purchase |
2024-09-30 | 13G | Edible Garden AG Incorporated EDBL |
Lind Global Fund II LP | 1,430 0.200% |
1,430 (New Position) |
Filing History |
| 2024-11-14 7:23 pm Purchase |
2024-09-30 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Lind Global Fund II LP | 3,125 1.200% |
3,125 (New Position) |
Filing History |
| 2024-11-14 7:22 pm Purchase |
2024-09-30 | 13G | PaxMedica, Inc. Common Stock PXMD |
Lind Global Fund II LP | 1,008,599 8.800% |
756,829 (+300.60%) |
Filing History |
| 2024-11-14 7:21 pm Sale |
2024-09-30 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC |
Lind Global Fund II LP | 0 0.000% |
-102,250 (Position Closed) |
Filing History |
| 2024-11-14 7:21 pm Purchase |
2024-09-30 | 13G | Cingulate Inc. CING |
Lind Global Fund II LP | 98,918 3.100% |
98,918 (New Position) |
Filing History |
| 2024-11-14 7:20 pm Sale |
2024-09-30 | 13G | BIOLASE INC PAR $.001 BIOLQ |
Lind Global Fund II LP | 0 0.000% |
-1,190,000 (Position Closed) |
Filing History |
| 2024-11-14 7:19 pm Unchanged |
2024-09-30 | 13G | Bone Biologics Corporation BBLG |
Lind Global Fund II LP | 34,180 1.900% |
0 (Unchanged) |
Filing History |
| 2024-11-14 7:18 pm Sale |
2024-09-30 | 13G | Mobiquity Technologies, Inc. MOBQ |
Lind Global Fund II LP | 122,695 0.800% |
-282,305 (-69.70%) |
Filing History |
| 2024-11-14 7:17 pm Purchase |
2024-09-30 | 13G | Kiora Pharmaceuticals, Inc. KPRX |
Lind Global Fund II LP | 109,160 3.500% |
109,160 (New Position) |
Filing History |
| 2024-11-14 7:16 pm Purchase |
2024-09-30 | 13G | Intelligent Bio Solutions Inc. INBS |
Lind Global Fund II LP | 151,515 3.400% |
151,515 (New Position) |
Filing History |
| 2024-11-14 7:15 pm Purchase |
2024-09-30 | 13G | Windtree Therapeutics, Inc. WINT |
Lind Global Fund II LP | 322 0.400% |
322 (New Position) |
Filing History |
| 2024-11-14 7:15 pm Sale |
2024-09-30 | 13G | ASLAN Pharmaceuticals Limited ASLN |
Lind Global Fund II LP | 0 0.000% |
-156,250 (Position Closed) |
Filing History |
| 2024-11-14 7:14 pm Purchase |
2024-09-30 | 13G | Tenax Therapeutics, Inc. TENX |
Lind Global Fund II LP | 375,000 9.900% |
375,000 (New Position) |
Filing History |
| 2024-11-14 7:13 pm Sale |
2024-09-30 | 13G | GSE Systems, Inc. GVP |
Lind Global Fund II LP | 250,000 9.900% |
-50,568 (-16.82%) |
Filing History |
| 2024-11-14 7:11 pm Purchase |
2024-09-30 | 13G | Golden Minerals Company AUMN |
Lind Global Fund II LP | 1,650,000 9.900% |
147,523 (+9.82%) |
Filing History |
| 2024-05-15 4:30 pm Purchase |
2023-12-31 | 13G | SenesTech, Inc. SNES |
Lind Global Fund II LP | 56,500 9.900% |
46,200 (+448.54%) |
Filing History |
| 2024-03-27 7:37 pm Purchase |
2024-03-22 | 13G | NLS Pharmaceutics AG NLSP |
Lind Global Fund II LP | 107,500 9.900% |
107,500 (New Position) |
Filing History |